期刊文献+

Ⅲ期非小细胞肺癌新辅助化疗后手术的预后因素分析 被引量:3

Analysis of Prognosis Factors for Operation after Neoadjuvant Therapy for Stage Ⅲ Non Small Cell Lung Cancer
下载PDF
导出
摘要 目的:探讨Ⅲ期非小细胞肺癌(NSCLC)新辅助化疗后影响手术并发症和生存期的相关危险因素。方法:152例ⅢA、ⅢB期NSCLC患者接受新辅助化疗和手术,收集其术前功能性指标、分期、并发疾病、化疗方法、手术方式、术后并发症、生存期等资料,采用卡方检验、Kaplan-Meier和Cox比例风险模型分别分析影响术后并发症和生存期的危险因素。结果:单因素分析显示第1秒用力呼气量占预计值百分比(FEV1%,P=0.040)和术前并发疾病(P=0.020)对手术并发症的发生有影响。Kaplan-Meier生存分析分期(P=0.050)和是否全肺切除(P=0.018)对术后生存时间有影响。进一步多因素Cox回归分析示,只有全肺切除对术后生存时间有影响(P=0.026),而左、右全肺切除无区别(P>0.05)。结论:Ⅲ期NSCLC新辅助化疗的术后并发症危险因素是可接受的。全肺切除是影响患者生存期的高危因素。 Objective:To explore the predictive factors for postoperative complications and survival time after neoadjuvant therapy for advanced stage Ⅲ non small cell lung cancer (NSCLC). Methods:One hundred fifty-two patients (116 males and 36 females) underwent neoadjuvant therapy and surgery for stage IliA and B NSCI.C. The demographic data, preoperative functional parameters, staging, associated disorders, chemotherapy or radiotherapy, type of operation, postoperative complication and survival time were collctecl. Chi square test was performed to identify predictors of postoperative complications, while Kaplan- Meier and multivariate Cox proportional hazard model were performed to identify predictors of survival time ,respectively. Results: The univariate analysis demonstrated that forced expiratory volume in 1 second predicted percent (FEV1 %, P = 0. 040) and associated disorders (P = 0. 1120) were the predictive factors of complications, Kaplan-Meier analysis showed that stage (P = 0. 050) and whether pneumonectorny or not (P=0. 018) affected the survival time. However, multivariate Cox proportional hazard model analysis demonstrated that only pneumonectomy (P = 0. 026) was associated with an decreased survival time with no differences between right and left pneumonectomy. Conclusion:The risk factor of complications is acceptable. Pneumonectomy is associated with an increased risk of mortality and should be performed in selected stage Ⅲ NSCLC patients.
出处 《中国临床医学》 2009年第5期714-716,共3页 Chinese Journal of Clinical Medicine
基金 中华人民共和国教育部博士点基金(20060487046)
关键词 非小细胞肺癌 新辅助化疗 手术 预后 Non small cell lung cancer Neoadjuvant therapy Surgery Prognosis
  • 相关文献

参考文献9

  • 1Georgios S. Risks of neoadjuvant chemotherapy and radiation therapy [J]. ThoracSurg Clin, 2008, 18:71 -80.
  • 2Shin-ichi T, Hajime M, Tatsuya O, et al, Results of pulmonary resection following neoadjuvant therapy for locally advanced (Ⅱ- ⅠA-ⅢB) lung cancer[J]. Eur J Cardiothorac Surg, 2006, 30: 184-189.
  • 3Perrot E, Guibert B, Mulsant P, et al. Preoperative chemotherapy does not increase complications after non small cell lung cancer resection[J]. Ann Thorac Surg,2005,80 : 423-427.
  • 4桑九高,徐小红.长春瑞宾持续静脉输注治疗晚期非小细胞肺癌[J].中国临床医学,2008,15(5):621-622. 被引量:1
  • 5Depierre A, Milleron B, Morat-Sibilot D, et ah Preoperative chemotherapy followed by surgery compared with primary surgery in respectable stage Ⅰ (except T1N0), Ⅱ and Ⅲa non small cell lung cancer[J]. J Clin Oncol, 2001,20:247-253.
  • 6Leo F, Solli PG, Veronesi G, et al. Does chemotherapy raise the risk of respiratory complications after pneumonectomy? [J]. J Thorae Cardiovasc Surg, 2006,132:519-523.
  • 7Rice TW, Okereke IC, Blachstone HH. Persistent air leaks following puhnonary resection[J]. Chest Surg Clin N Am, 2002, 12:529- 539.
  • 8Federico V, Marco A, Daniele D, et al. Operative complications and early mortality after induction therapy for lung cancer[J]. Eur J Cardiothorac Surg, 2007, 31:714-718.
  • 9Martin J, Ginsberg RJ, Abolhoda A, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy[J]. Ann Thorac Surg, 2001, 72: 1149- 1154.

二级参考文献3

同被引文献19

  • 1Rosell R,Lord RV,Taron M,et al.DNA repair and cisplatin resistance in non-small cell lung cancer[J].Lung Cancer,2002,38(3):217.
  • 2Rosell R,TaronM,BarnadasA,et al Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer[J].Cancer Contro,2003,10(4):297-305.
  • 3Soria J,Haddad V,Olaussen KA,et al Immunohistochemical staining of the excision repair cross-complementing 1 (ERCC1) protein as predictor for benefit of adjuvant chemotherapy (CT) in the International Lung Cancer Trial (IALT)[J].J Clin Oncol,2006,24(suppl),Abstract:7010.
  • 4RosellR,CoboM,IsLaD,et al.ERCC1 mRNA-based randomized phaseⅢ trial of docetaxel (doc) doublets with cisplatin(cis) or gemcitabine (gem) in stageⅣnon-small-cell lung cancer (NSCLC) patients (p)[J].J CLin Onco,2005,23(suppl):621.
  • 5Wachtersa FM,Wongb LSM,Timensc W,et al.ERCC1,hRad51,and BRCA1 protein expression in relation to tumour response and survival of stageⅢ/ⅣNSCLC patients treated with chemotherapy[J].Lung Cancer,2005,50:211-219.
  • 6Groome PA,Bolejack V,Crowley JJ,et al.IASLC International Staging Committee; Cancer Research And Biostatistics; Observers To The Committee; Participating Institutions.The IASLC lung cancer staging project:validation of the proposals for revision of the T,N,and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours[J].Journal of Thoracic Oncology,2007,2:694-705.
  • 7Rosell R,Gomez-Codina J,Camps C,et al.A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer[J].New England Journal of Medicine,1994,330:153-158.
  • 8Elias AD,Skarin AT,Leong T,et al.Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC)[J].Lung Cancer,1997,17:147-161.
  • 9Berghmans M,Paesmans A P,Meert C et al.Sculier survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy:results of a meta-analysis of the literature[J].Lung Cancer,2005,49(1):13-23.
  • 10PFANNSCHMIDT J, M ULEY T, BULZEBRUCK H, et al. Prog- nostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients [J]. Lung Cancer, 2007(55): 371-377.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部